In an aggressive push to end hepatitis C in England, health authorities there are in the process of weighing bids in NHS England’s “largest ever” drug procurement process. But AbbVie isn’t happy with the negotiations, and it’s suing the health service for treating bidders unfairly, according to England’s Health Service Journal (HSJ).
AbbVie, which makes the fast-growing Mavyret, claimed the National Health Service broke procurement rules in its effort to buy hundreds of millions of pounds worth of hepatitis C drugs, HSJ reported. The NHS wants to buy the drugs in bulk to keep costs down as it works to eliminate hep C in England by 2025.
Along with AbbVie, Gilead Sciences, Janssen and Merck & Co. have also bid, according to the publication. Merck is known as MSD in England.